Loading...
Market
Geographical Regions for HRO761 Phase 1 Trials by End of 2025
2
Resolution / Starting Odds
North America • 20%
Europe • 20%
Asia • 20%
Australia • 20%
Multiple regions • 20%
Clinical trials registration data, press releases from NIBR or Vividion
Story
Breakthrough WRN Inhibitor HRO761 Targets MSI Cancers, Poised for Clinical Trials
Apr 24, 2024, 07:56 PM
Recent research has led to the discovery of a novel inhibitor, HRO761, targeting Werner Helicase (WRN), which shows synthetic lethality in microsatellite instability (MSI) cancers. This breakthrough, published in Nature, was achieved through chemoproteomic techniques that identified a covalent allosteric inhibitor of WRN. The research, spearheaded by NIBR and involving Vividion, marks a significant advancement in cancer treatment, particularly by transforming an ATP-competitive compound into an ATP-cooperative analogue. The development is poised for clinical testing to evaluate its effectiveness in human models of disease.
View original story
Similar markets
United States • 25%
European Union • 25%
Japan • 25%
South Korea • 25%
North America • 25%
Europe • 25%
Asia • 25%
Global (Simultaneous Multi-Region) • 25%
North America • 25%
Europe • 25%
Asia • 25%
Rest of the World • 25%
Southeast Asia • 33%
South America • 33%
Central America • 34%
North America • 20%
Europe • 20%
Asia • 20%
South America • 20%
Australia • 20%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Rest of World • 25%
Phase 4 trial initiated • 33%
Additional Phase 3 trial initiated • 33%
No further trials announced • 33%
North America • 25%
Europe • 25%
Asia • 25%
Rest of the World • 25%
Phase 4 trial • 25%
Approval in additional markets • 25%
Development of new formulations • 25%
Strategic partnership or collaboration • 25%
Does not progress past Phase 1 • 25%
Completes Phase 1 but not Phase 2 • 25%
Completes Phase 2 but not Phase 3 • 25%
Advances to Phase 3 or beyond • 25%